Eolo Pharma, a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, today announced the publication of its first-in-human study in Nature Metabolism, ...

The collaboration will combine O2nix Bio’s proprietary biology platform and scientific leadership in tRNA methylation with Synfini’s AI Cloud Foundry, an end-to-end automated system that accelerates ...

Built in 2018, this high quality residence is expected to reach stabilized occupancy of 95% within the next 12 months, supported by the rapidly improving supply-demand fundamentals in the Ottawa ...

CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, today announced it has become the first healthcare company to establish a ...

“Josh is the right leader for Bay Area Lyme Foundation as we enter this exciting new chapter,” said Bonnie Crater, founder and co-chair of the Board of Directors of Bay Area Lyme Foundation. “With his ...

The 113th Congress of Japan Society of Aesthetic Surgery Venue：The Okura Tokyo Dates：Wednesday, May 28 – Friday, May 30, 2025 ...

AZD5004/ECC5004 is an investigational oral small molecule GLP-1 receptor agonist, which is currently being investigated for the treatment of type 2 diabetes and obesity or overweight with at least one ...

Integration of new ancillary systems to increase throughput and optimize molding and assembly workflows ...

WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the ...

Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to ...

Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin ...

BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development. The Company plans to seek guidance in Q3 2025 ...